Summary Tumour samples from 150 patients with squamous cell carcinoma of the oesophagus were investigated immunohistochemically with the monoclonal antibody MIB-I, which recognises proliferating cells. Using light microscopy, the number of MIB-I-positive tumour cells was counted in the areas with the highest proliferative activity. The MIB-1 index was determined as the proportion of MIB-I-positive and MIB-1-negative tumour cells. A considerable variation of the MIB-1 indices was found between the different tumours with a minimum of 6% and a maximum of 95% (median, 33%). The MIB-1 index correlated significantly with the mitotic activity in the tumour tissue (r =0.33; P=0.0001) and with the proportion of apoptotic tumour cells (r=0.25; P=0.0017). No significant correlation was found between the MIB-1 index and various other prognostic parameters including pT classification, pN classification, tumour size, tumour grade, blood vessel invasion and lymphatic vessel invasion. In the univariate survival analysis no significant difference was found between tumours with low (<33%) and high MIB-1 index (>33%) (5-year survival rate: low MIB-1 index, 19.2%; high MIB-1 index, 22.2%). In a Cox proportional hazard regression analysis only the parameters lymphatic vessel invasion (P=0.0001), pT classification (P=0.0034) and pN classification (P=0.0256), but not the MIB-1 index, could be verified as independent prognostic variables. In conclusion, evaluation of the MIB-1 index does not provide prognostic information for oesophageal cancer patients.
The stage of tumour growth, as defined by the TNM classification (UICC, 1992) , is the accepted basis for predicting the prognosis of cancer patients. Nevertheless, efforts have been made to define new prognostic parameters which might improve accuracy in the prediction of patients' outcome. In this context, the measurement of the tumour growth fraction offers a potentially valuable approach for predicting the clinical course and the response to therapy in patients with cancer (Tannock, 1987) . Thus, in breast cancer (Gasparini et al., 1992; Clayton, 1991) , in non-Hodgkin's lymphoma (Hall et al., 1988) and soft-tissue sarcomas (Trojani et al., 1984) the proliferative activity of the tumour tissue is regarded as a prognostic factor independent of known clinicopathological indicators.
One of the methods most frequently used to determine the proportion of proliferating cells in malignant tumours is the immunohistochemical detection of the nuclear Ki-67 antigen, which is only expressed in proliferating, but not in resting cells (Gerdes et al., 1984) . A good correlation has been shown between the immunohistochemical labelling of cell nuclei with Ki-67 and other methods of assessing cell proliferation, e.g. mitosis counts (Weidner et al., 1994) , bromodeoxyuridine labelling (Yonemura et al., 1990) , flow cytometry (Walker et al., 1988) , thymidine labelling (Kamel et al., 1989) and autoradiography (Gerdes et al., 1984) . Recently, the requirement of frozen sections for Ki-67 immunohistochemistry has been overcome by the generation of the monoclonal MIB-1 antibody, which recognises a fixation-resistant epitope of the Ki-67 antigen (Cattoretti et al., 1992) . This provides the opportunity to test the prognostic significance of tumour cell proliferation on large retrospective series of different types of human cancer.
Only a few studies are available concerning the proliferative activity of squamous cell carcinomas of the oesophagus (SCC Given the impression of these few and inconclusive results, the present study was undertaken to investigate the possible prognostic significance of tumour cell proliferation as determined by the MIB-1 antibody in a series of 150 oesophageal cancer patients who underwent potential curative resection therapy. The question to be followed up was whether in oesophageal cancer, as in some other tumour types, rapidly proliferating carcinomas display a more unfavourable outcome than slowly proliferating carcinomas.
Materials and methods Patients
The study comprised 150 patients who underwent potentially curative resection for squamous cell carcinoma (SCC) Mitotic and apoptotic tumour cells were counted in ten randomly selected microscopic fields (corresponding to a total of at least 1000 tumour cells), by using a quadratic reticle with 25 squares of 4 mm2 inserted in a x 10 ocular lens (Del Vecchio et al., 1991) . For the random selection of microscopic fields, each sample was initially examined at low-power magnification ( x 4 objective lens and x 10 ocular lens) in order to exclude areas of ulceration and necrosis. Subsequently, mitotic figures and apoptotic bodies were counted in ten microscopic fields under high-power magnification ( x 40 objective lens and x 10 ocular lens), starting in the centre of the tumour and subsequently shifting into different parts of the tumour, without taking account of tumour differentiation and proliferative activity. Apoptotic cells were identified by cell shrinkage, with condensed chromatin, and often deeply eosinophilic cytoplasm (Staunton and Gaffney, 1995) . Mitotic figures were separated from apoptotic cells according to the following criteria (Baak, 1990) : (1) absence of nuclear membrane; (2) absence of clear zone in centre; (3) presence of hairy instead of triangular or spiky projections; and (4) basophilia of surrounding cytoplasm instead of eosinophilia. The mitotic index (MI) and apoptotic index (Al) per case were expressed as percentages, i.e. as the mean number of mitotic figures or apoptotic bodies per 100 intact tumour cells.
Accordingly, the median MI was 0.8 (mean 0.8; range 0.1-3.1) and the median Al was 0.9 (mean 1.0; range 0.1-3.8).
Assessment of proliferative activity by MIB-1 staining Consecutive sections from the paraffin blocks used for the assessment of mitotic and apoptotic indices were stained with the monoclonal antibody MIB-1 (Dianova, Hamburg, Germany), which recognises a fixation-resistant epitope of the Ki-67 antigen (Cattoretti et al., 1992) . Sections were placed on slides coated with 3-aminopropyltriethoxy-silane (Sigma, Deisenhofen, Germany). After microwave pretreatment in citrate buffer (pH 6.0) three times for 5 min at 750 W, the slides were stained using the avidin-biotin complex technique (Hsu et al., 1981) . The primary antibody was diluted 1:10 with phosphate-buffered saline (PBS). The slides were finally counterstained with haemalaune. Tonsils were used as positive controls and negative controls were performed by replacing the primary antibody with PBS. The number of MIB-1-positive tumour cell nuclei and the total number of tumour cell nuclei were counted by light microscopy, again using a quadratic reticle with 25 squares of 4 mm2 inserted in a x 10 ocular combined with a x 40 objective. A minimum of 1000 nuclei per tumour was counted in the areas of the highest proliferative activity (Weidner et al., 1994 (Figure 1 ). In normal oesophageal mucosa adjacent to the tumour tissue the MIB-1 expression was always confined to the basal cell layer.
The proportion of MIB-1-positive tumour cells varied widely between the different tumours. Thus, the minimum MIB-1 index was 6% and the maximum MIB-l index was 95% (median 33%; mean+s.d. 41.5%+24.2; Figure 2 ). Moreover, a heterogeneous intratumoral distribution of MIB-1-positive tumour cells was found in many tumours. In general, the highest proportion of MIB-1-positive tumour cells was found at the tumour margins.
Correlation between mitotic index (MI), apoptotic index (AI) and MIB-J index The proportion of MIB-1-positive tumour cells ran parallel with-MI and Al in the tumour tissue, showing higher proportions of mitotic and apoptotic tumour cells in cases with high MIB-1 indices than in cases with low MIB-1 indices. According to the Spearman rank correlation test, there was a closer association between mitotic activity and MIB-1 expression (r=0.33; P= 0.0001) than between the number of apoptotic tumour cells and MIB-1 expression (r=0.25; P=0.0017).
Correlation between MIB-1 index and other prognostic parameters (Table I) There was a tendency for higher MIB-1 indices to occur in poorly differentiated tumours than in highly differentiated tumours. The mean MIB-1 index increased continuously from 36.7% in GI carcinomas to 48.9% in G4 carcinomas. However, this correlation failed to achieve statistical Original magnification x 300. Bar=50/,um. Survival analysis (Table II) For survival analysis the patients were stratified by the median MIB-1 index into a group of patients with rapidly proliferating tumours (MIB-1 index >33%) and a group of patients with slowly proliferating tumours (MIB-1 index .33%). No differences in survival were found between these two groups of patients. Owing to the fact that there was a relative maximum of tumours with 40% or less of MIB-1-positive tumour cells (Figure 2) , we additionally evaluated the .40%: 40.9%/ 18.6%; MIB-1 index >40%: 37.5%/ 24.5%; P=0.9810). Moreover, no significant differences in survival were found when the patients were stratified by the 10 percentile, 30 percentile, 70 percentile or 90 percentile of MIB-1 indices respectively (data not shown). Finally, no significant differences in survival were found when the prognostic influence of the MIB-1 index was investigated separately either in lymph node-negative or lymph nodepositive carcinomas.
In a forward multivariate Cox regression analysis, including the parameters pT classification, pN classification, tumour grade, MIB-1 index, age, sex, tumour size, lymphatic vessel invasion and blood vessel invasion, only the parameters lymphatic vessel invasion (P= 0.0001), pT classification (P=0.0034) and pN classification (P=0.0256), but not the MIB-1 index, could be verified as independent prognostic variables. The current study shows that the proportion of MIB-1-expressing tumour cells in oesophageal cancer is not correlated to prognostic parameters such as pT classification, pN classification and tumour size. Moreover, the MIB-1 index has no impact on the outcome of oesophageal cancer patients.
The MIB-1 indices obtained in our study are in line with the results of earlier studies that had used the Ki-67 antibody (Porschen et al., 1991) and the MIB-1 antibody (Youssef et al., 1995) on oesophageal carcinomas. Thus, the mean Ki-67 index in the study of Porschen et al. (1991) (35.7%) and the cut-off value to define low and high MIB-1 indices (mean or median were not given) in the study of Youssef et al. (1995) (30%) are very close to the median (33%) found in our study. Furthermore, we found a reasonable correlation between mitotic activity and MIB-1 immunoreactivity in our tumour material. Thus, it can be concluded that the immunohistochemical evaluation of formalin-fixed tumour samples using the MIB-1 antibody gives a reliable estimation of the proportion of proliferating tumour cells in oesophageal cancer specimens.
The rate at which a tumour proliferates is traditionally considered to bear a relationship to its clinical course. The simplest and most established method for determining the proliferative activity of a tumour is the counting of mitotic figures. However, mitotic counts are not completely reliable or reproducible (Quinn and Wright, 1990 (Bouzubar et al., 1989; Gasparini et al., 1992; Railo et al., 1993) (Steel, 1967) .
Various methods for the determination of the Ki-67 index or the MIB-1 index have been used by different investigators. Thus, in some studies the counting of immunostained tumour cell nuclei was performed using computer-assisted image analysis (Kubota et al., 1992; Simony et al., 1990) , whereas the majority of the scientists directly counted immunoreactive tumour cells using light microscopy. The number of cells which need to be counted to obtain a representative sample is not yet clearly defined, but a figure of 500 is generally considered a minimum requirement (Brown and Gatter, 1990) . In some studies, more than one block of tumour tissue was immunostained with Ki-67/MIB-1 in order to take account of intratumoral heterogeneity in proliferative activity (Simony et al., 1990) . However, as outlined in the study of Simony et al. (1990) , who investigated Ki-67 labelling in nonsmall-cell lung cancer, the variation of Ki-67 indices between different tumours (intertumoral heterogeneity) is 15 times higher than between different regions of one tumour (intratumoral heterogeneity). Thus, Ki-67/MIB-1 staining of more than one tumour block does not seem to be necessary for distinguishing between slowly and rapidly proliferating tumours. Moreover, the selection of multiple tumour blocks would substantially increase the costs for immunohistochemistry and require additional time for determination of the labelling index, thus making this method unsuitable for routine surgical pathology (Simpson and Page, 1994) .
In conclusion, the proportion of MIB-1-expressing tumour cells in SCC of the oesophagus is not correlated to the established prognostic parameters including pTNM stage, tumour size and tumour grade. The determination of the proliferative activity of oesophageal cancers does not currently provide useful prognostic information.
